Duchenne Muscular Dystrophy Drugs Global Market Report 2025
상품코드:1760527
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
듀셴형 근이영양증(DMD) 치료제 시장 규모는 향후 몇 년 동안 13.8%의 연평균 성장률로 2029년 54억 2,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간의 성장은 초기 단계의 바이오테크 기업 진입 증가, 실제 임상 증거 및 시판 후 데이터 증가, 의료비 지출 증가, 조기 개입 치료에 대한 수요 증가, 적응증 외 코르티코스테로이드 사용 확대 등에 기인하는 것으로 보입니다. 이 기간의 주요 동향으로는 생명공학을 통한 기술 혁신의 급증, 디지털 헬스 및 웨어러블 기술의 통합, 맞춤형 치료 및 돌연변이 특이적 치료에 대한 관심 증가, 유전자 치료 및 CRISPR 기술의 발전 등을 꼽을 수 있습니다.
맞춤의료에 대한 관심이 높아지면서 듀셴형 근이영양증(DMD) 치료제 시장의 성장을 크게 견인할 것으로 예상됩니다. 맞춤의료는 유전적, 환경적, 생활습관적 요인에 따라 환자 개개인에게 맞춤화된 치료를 통해 결과를 최적화하고 치료를 강화하는 것입니다. 맞춤의료에 대한 수요 증가는 유전체 기술의 발전으로 인해 유전적 변이를 정확하게 파악하여 개인별 맞춤 치료법을 개발할 수 있게 되었기 때문입니다. 맞춤형 의료는 유전자 프로파일에 기반한 표적 치료를 제공함으로써 치료를 보다 효과적으로 만들어 DMD 치료제의 효과를 높일 수 있습니다. 또한, 특정 유전자 변이에 집중함으로써 약물 개발이 용이해져 치료 성과와 환자 치료 전반을 개선할 수 있습니다. 예를 들어, 2024년 2월 미국 비영리단체인 개인맞춤의료연합(PMC)은 미국 식품의약국(FDA)이 2023년 26개의 맞춤형 신약을 승인했다고 보고했습니다. 따라서 맞춤의료의 성장은 DMD 치료제 시장의 주요 촉진요인입니다.
듀셴형 근이영양증(DMD) 치료제 시장의 주요 기업들은 근력을 향상시키고, 질병의 진행을 늦추며, 환자의 예후를 개선하기 위해 부신피질 스테로이드와 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 부신피질 스테로이드는 부신에서 자연적으로 분비되는 스테로이드 호르몬으로 염증을 억제하고 면역 체계를 억제하는 약물로 합성됩니다. 예를 들어, 2024년 3월 미국 바이오 제약사 카탈리스트 파마슈티컬스는 2세 이상 DMD 환자를 대상으로 한 FDA 승인 치료제인 아가몰리(바몰로론) 경구 현탁액 40mg/mL를 출시하였습니다. 아가믈리(Agamry)는 부신피질 스테로이드 약물로 염증을 억제하고 근세포막을 안정화시켜 질환의 진행을 지연시키는 효과가 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 듀셴형 근이영양증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 듀셴형 근이영양증 치료제 시장 : 성장률 분석
세계의 듀셴형 근이영양증 치료제 시장 실적 : 규모와 성장, 2019-2024년
세계의 듀셴형 근이영양증 치료제 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 듀셴형 근이영양증 치료제 전체 시장(TAM)
제6장 시장 세분화
세계의 듀셴형 근이영양증 치료제 시장 : 약물 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
엑손 스키핑 약
코르티코스테로이드
유전자 치료
기타 약물 종류
세계의 듀셴형 근이영양증 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
경구
주사제
세계의 듀셴형 근이영양증 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원 약국
소매 약국
온라인 약국
세계의 듀셴형 근이영양증 치료제 시장, 엑손 스키핑 약 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Eteplirsen
Golodirsen
Viltolarsen
Casimersen
기타 엑손 스키핑 요법
세계의 듀셴형 근이영양증 치료제 시장, 코르티코스테로이드 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
Prednisone
Deflazacort
기타 코르티코스테로이드
세계의 듀셴형 근이영양증 치료제 시장, 유전자 치료 종류별 하위 세분화, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
마이크로 디스트로핀 유전자 치료
CRISPR/Cas9 기반 유전자 편집
줄기세포를 이용한 유전자 치료
기타 유전자 치료
세계의 듀셴형 근이영양증 치료제 시장, 기타 약물 유형 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
유트로핀 모듈레이터
항염증제
안티센스 올리고뉴클레오티드
미오스타틴 억제제
기타 지지요법
제7장 지역별·국가별 분석
세계의 듀셴형 근이영양증 치료제 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 듀셴형 근이영양증 치료제 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
듀셴형 근이영양증 치료제 시장 : 경쟁 구도
듀셴형 근이영양증 치료제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
GSK plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Eli Lilly and Company
Aurobindo Pharma Limited
Italfarmaco S.p.A
Sarepta Therapeutics Inc.
PTC Therapeutics Inc.
FibroGen Inc.
Wave Life Sciences Ltd.
Solid Biosciences Inc.
NS Pharma
Capricor Therapeutics Inc.
Santhera Pharmaceuticals
ReveraGen BioPharma
Antisense Therapeutics Limited
Catalyst Pharmaceuticals Inc.
EspeRare Foundation
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
듀셴형 근이영양증 치료제 시장 2029년 : 새로운 기회를 제공하는 국가
듀셴형 근이영양증 치료제 시장 2029년 : 새로운 기회를 제공하는 부문
듀셴형 근이영양증 치료제 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Duchenne muscular dystrophy (DMD) drugs are medications and therapies designed to manage and slow the progression of Duchenne muscular dystrophy, a genetic disorder that leads to muscle weakness and degeneration. These drugs target the underlying genetic mutations, improve muscle function, and enhance quality of life. The primary goal of these drugs is to preserve muscle strength, delay disease progression, and increase mobility in individuals with DMD.
The main types of drugs in the duchenne muscular dystrophy market include exon skipping drugs, corticosteroids, gene therapy, and other treatments. Exon skipping drugs are specialized therapies that enable the body to produce a functional, albeit shorter, version of the dystrophin protein by bypassing defective sections of the dystrophin gene during protein synthesis. These drugs are administered through oral and injectable routes, and they are distributed via several channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The Duchenne muscular dystrophy drugs market research report is one of a series of new reports from The Business Research Company that provides Duchenne muscular dystrophy drugs market statistics, including Duchenne muscular dystrophy drugs industry global market size, regional shares, competitors with a Duchenne muscular dystrophy drugs market share, detailed Duchenne muscular dystrophy drugs market segments, market trends and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy drugs industry. This Duchenne muscular dystrophy drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The duchenne muscular dystrophy (DMD) drug market size has grown rapidly in recent years. It will grow from $2.83 billion in 2024 to $3.23 billion in 2025 at a compound annual growth rate (CAGR) of 14.2%. The growth during the historic period can be attributed to advancements in diagnostic capabilities, the expansion of patient registries and data collection, a surge in demand for DMD treatments, a growing pipeline of clinical-stage therapies, and increased regulatory incentives.
The duchenne muscular dystrophy (DMD) drug market size is expected to see rapid growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to the rise of early-stage biotech entrants, an increase in real-world evidence and post-marketing data, higher health expenditure, growing demand for early intervention treatments, and an expansion in off-label corticosteroid use. Major trends during this period include a surge in biotech innovation, the integration of digital health and wearable technology, growing interest in personalized and mutation-specific therapies, and advancements in gene therapy and CRISPR technologies.
The increasing focus on personalized medicine is expected to significantly drive the growth of the Duchenne muscular dystrophy (DMD) drugs market. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors, optimizing outcomes and enhancing care. The rising demand for personalized medicine is largely due to advancements in genomic technologies, which allow for the precise identification of genetic variations and the development of treatments tailored to individual needs. Personalized medicine benefits DMD drugs by offering targeted therapies based on genetic profiles, making treatments more effective. It also facilitates drug development by concentrating on specific genetic mutations, thus improving treatment outcomes and overall patient care. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a substantial increase from the 12 approved in 2022. Therefore, the growth of personalized medicine is a key driver of the DMD drugs market.
Leading companies in the Duchenne muscular dystrophy (DMD) drugs market are focusing on developing innovative solutions, such as corticosteroids, to improve muscle strength, slow disease progression, and enhance patient outcomes. Corticosteroids are steroid hormones naturally produced by the adrenal glands or synthesized as medications to reduce inflammation and suppress the immune system. For instance, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, launched AGAMREE (vamorolone) oral suspension 40 mg/mL, an FDA-approved treatment for DMD in patients aged two and older. AGAMREE is a corticosteroid that works by reducing inflammation and stabilizing muscle cell membranes, which helps slow disease progression.
In July 2023, Catalyst Pharmaceuticals, a US-based biopharmaceutical company, acquired an exclusive North American license for vamorolone (AGAMREE), a DMD drug, from Santhera Pharmaceuticals for an undisclosed amount. This acquisition allows Catalyst Pharmaceuticals to expand its portfolio and offer a more effective treatment option for DMD patients, addressing the growing demand for safer and more targeted therapies. Santhera Pharmaceuticals, a Switzerland-based company, specializes in developing innovative therapies for Duchenne muscular dystrophy.
Major players in the duchenne muscular dystrophy drugs market are Pfizer Inc., Sanofi S.A., Bristol-Myers Squibb, Novartis AG, GSK plc, Eli Lilly and Company, Aurobindo Pharma Limited, Italfarmaco S.p.A, Sarepta Therapeutics Inc., PTC Therapeutics Inc., FibroGen Inc., Wave Life Sciences Ltd., Solid Biosciences Inc., NS Pharma, Capricor Therapeutics Inc., Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc., EspeRare Foundation, Satellos Bioscience Inc.
North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Duchenne muscular dystrophy (DMD) drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Duchenne muscular dystrophy (DMD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The Duchenne muscular dystrophy (DMD) drugs market consists of sales of utrophin modulators, anti-inflammatory agents and myostatin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Duchenne Muscular Dystrophy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3. Duchenne Muscular Dystrophy Drugs Market Trends And Strategies
4. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Duchenne Muscular Dystrophy Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Duchenne Muscular Dystrophy Drugs Market Growth Rate Analysis
5.4. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM)
6.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exon Skipping Drugs
Corticosteroids
Gene Therapy
Other Drug Types
6.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Eteplirsen
Golodirsen
Viltolarsen
Casimersen
Other Exon Skipping Therapies
6.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisone
Deflazacort
Other Corticosteroids
6.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Micro-dystrophin Gene Therapy
CRISPR/Cas9-Based Gene Editing
Stem Cell-Based Gene Therapy
Other Gene Therapies
6.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Utrophin Modulators
Anti-Inflammatory Agents
Antisense Oligonucleotides
Myostatin Inhibitors
Other Supportive Therapies
7. Duchenne Muscular Dystrophy Drugs Market Regional And Country Analysis
7.1. Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Duchenne Muscular Dystrophy Drugs Market
9.1. China Duchenne Muscular Dystrophy Drugs Market Overview
9.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Duchenne Muscular Dystrophy Drugs Market
10.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Duchenne Muscular Dystrophy Drugs Market
11.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview
11.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Duchenne Muscular Dystrophy Drugs Market
12.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Duchenne Muscular Dystrophy Drugs Market
13.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Duchenne Muscular Dystrophy Drugs Market
14.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview
14.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Duchenne Muscular Dystrophy Drugs Market
15.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview
15.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Duchenne Muscular Dystrophy Drugs Market
16.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Duchenne Muscular Dystrophy Drugs Market
18.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Duchenne Muscular Dystrophy Drugs Market
21.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview
21.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Duchenne Muscular Dystrophy Drugs Market
22.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Duchenne Muscular Dystrophy Drugs Market
23.1. North America Duchenne Muscular Dystrophy Drugs Market Overview
23.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Duchenne Muscular Dystrophy Drugs Market
24.1. USA Duchenne Muscular Dystrophy Drugs Market Overview
24.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Duchenne Muscular Dystrophy Drugs Market
26.1. South America Duchenne Muscular Dystrophy Drugs Market Overview
26.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Duchenne Muscular Dystrophy Drugs Market
27.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Duchenne Muscular Dystrophy Drugs Market
28.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview
28.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Duchenne Muscular Dystrophy Drugs Market
29.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview
29.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles
